Bivalent Vaccine: A Complete Guide to bivalent Vaccination and Cancer Prevention

The term became widely discussed during the COVID-19 pandemic when vaccine manufacturers developed formulations targeting the original SARS-CoV-2 strain together with an Omicron variant. In 2022, the U.S. Food and Drug Administration (FDA) advised manufacturers developing modified COVID-19 booster vaccines to include an Omicron BA.4/BA.5 component alongside the original vaccine composition.

It is important to distinguish bivalent vaccines used historically or during earlier COVID-19 vaccination campaigns from currently recommended COVID-19 vaccine formulations. Current COVID-19 vaccine recommendations have moved toward updated formulations designed around more recent circulating virus lineages.

What Is a Bivalent Vaccine?

Definition of Bivalent Vaccines

A bivalent vaccine contains components intended to stimulate immunity against two targets. These targets may be two strains, variants, or antigenic forms of the same pathogen.

For example, a vaccine may be designed to recognize:

• An earlier strain of a virus
• A newer variant
• Two related viral antigens
• Two different forms of an antigen

The objective is to broaden the immune response compared with a formulation targeting only one component.

Bivalent vs. Monovalent Vaccines

The main distinction is the number of antigenic targets.

The term describes the composition of the vaccine, not automatically how effective or appropriate it is for every person.

How Does a Bivalent Vaccine Work?

Immune System Response

Vaccines expose the immune system to specific antigenic information without requiring exposure to the disease itself. The immune system can then develop antibodies and other immune responses that help recognize the targeted pathogen.

With a bivalent formulation, two related targets are included. This can allow the immune system to develop recognition across both components.

Broader Antigen Coverage

One reason researchers develop multivalent vaccines is to address differences between circulating strains or variants.

However, protection depends on several factors, including:

• The vaccine formulation
• The pathogen and its mutations
• Previous vaccination
• Previous infection
• Age and immune status
• Time since vaccination
• The ability of circulating strains to match vaccine targets

Therefore, the word bivalent alone does not establish the level of protection a particular vaccine provides.

Bivalent COVID-19 Vaccines

Why Were Bivalent COVID-19 Vaccines Developed?

SARS-CoV-2 evolved substantially during the COVID-19 pandemic. The emergence of Omicron and its subvariants created a need to evaluate whether vaccine composition should be updated.

In June 2022, the FDA recommended that manufacturers seeking to modify COVID-19 booster vaccines develop formulations containing an Omicron BA.4/BA.5 component alongside the original composition.

These formulations became known as bivalent COVID-19 vaccines because they targeted the original strain and an Omicron component.

How COVID-19 Vaccine Formulations Have Changed

COVID-19 vaccine formulations have continued to evolve as researchers and regulators assess circulating SARS-CoV-2 lineages.

For the 2025–2026 U.S. vaccination season, CDC guidance described updated formulations based on the Omicron JN.1 lineage, with Moderna and Pfizer-BioNTech formulations based on LP.8.1 and Novavax based on JN.1.

For the 2026–2027 season, CDC guidance now describes updated COVID-19 vaccines rather than the older bivalent formulations.

This distinction is important when researching bivalent vaccine availability, because older bivalent COVID-19 formulations should not automatically be assumed to represent the current vaccine formulation.

Potential Benefits of Bivalent Vaccine Technology

Broader Immune Targeting

A two-component formulation can provide the immune system with information about more than one antigenic target.

This approach may be useful when a pathogen changes over time and different strains share important but distinct characteristics.

Adaptation to Viral Variants

Vaccine composition can be updated as scientific evidence about circulating variants develops. COVID-19 vaccine development provides an important example of this continuing process.

Support for Public Health

Vaccination is one component of broader public-health strategies intended to reduce serious disease and complications associated with infectious diseases.

Current CDC guidance states that COVID-19 vaccination is intended to prevent COVID-19 and its complications, with recommendations taking age and immune status into account.

Bivalent Vaccine Safety

Common Vaccine Reactions

Like other vaccines, vaccination can be associated with temporary reactions. Depending on the vaccine, these may include:

• Pain or tenderness at the injection site
• Fatigue
• Headache
• Muscle aches
• Mild fever
• Chills

The specific safety profile depends on the individual vaccine and its formulation.

Serious Reactions

Serious adverse reactions are uncommon, but they can occur with vaccines. Vaccine information provided by the relevant health authority or manufacturer contains detailed information about contraindications, warnings, and possible adverse reactions.

People with questions about vaccination, previous vaccine reactions, allergies, pregnancy, or immune conditions should discuss their circumstances with an appropriately qualified healthcare professional.

Who May Need Vaccination?

Age and Health Status Matter

There is no single vaccination schedule that applies to everyone. Recommendations can depend on:

• Age
• Previous vaccination history
• Immune status
• Underlying risk factors
• Pregnancy
• Current public-health recommendations

For example, CDC guidance for the 2026–2027 COVID-19 season recommends an updated COVID-19 vaccine for adults and provides different considerations for children and people with moderate or severe immunocompromise.

Individual Vaccination Decisions

Vaccination recommendations can change as new evidence becomes available. People should use current guidance from relevant public-health authorities and healthcare professionals rather than relying on older information about bivalent COVID-19 vaccines.

Bivalent Vaccine vs. Updated Vaccine

The terms can sometimes cause confusion.

A bivalent vaccine specifically describes a formulation with two antigenic targets.

An updated vaccine describes a formulation that has been modified to reflect newer scientific information, such as changes in circulating pathogen strains.

An updated vaccine is not necessarily bivalent.

This distinction is particularly important for COVID-19 because vaccine formulations have changed since the introduction of the original bivalent products.

Frequently Asked Questions

What does bivalent mean in vaccines?

Bivalent means that a vaccine is designed around two antigenic targets, such as two strains or variants of a pathogen.

Is a bivalent vaccine the same as an updated vaccine?

No. Bivalent refers to the number of principal antigenic targets, while updated refers to a formulation that has been modified based on newer evidence.

Are bivalent COVID-19 vaccines still the current formulation?

Not necessarily. COVID-19 vaccine formulations have been updated over time. Current U.S. guidance for the 2026–2027 season concerns updated COVID-19 vaccines rather than the older bivalent formulations.

Does bivalent mean a vaccine provides complete protection?

No. Vaccine protection is not absolute, and the level and duration of protection vary by vaccine, pathogen, variant, individual characteristics, and time since vaccination.

Where can reliable vaccine information be found?

For current COVID-19 vaccination information, reputable sources include national public-health authorities, regulatory agencies, and healthcare professionals. CDC guidance is updated as recommendations and scientific information change.

Conclusion

A bivalent vaccine is a vaccine formulation designed to target two antigenic components. The technology became particularly prominent during the COVID-19 pandemic when formulations were developed to address both the original SARS-CoV-2 strain and an Omicron component.

However, vaccine science continues to evolve. Current COVID-19 vaccines have moved beyond the earlier bivalent formulations toward updated compositions designed around more recent circulating SARS-CoV-2 lineages.

For accurate vaccination information, readers should check the latest recommendations from appropriate health authorities because eligibility, formulations, schedules, and guidance can change over time.

Note: This article is for general educational information and does not replace advice from a qualified healthcare professional.